Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 28, 2024Open Forum Infectious DiseasesOpen Access

Risk of Invasive Fungal Infections in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors: A Case-Control Propensity Score–Matched Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

NHNelson Iván Agudelo HiguitaDCDaniel B. ChastainBSBrian T. Scott

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Higuita et al. (2024) studied this question.

synapsesocial.com/papers/68e77206b6db6435876e6f7fhttps://doi.org/10.1093/ofid/ofae115
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors – systematic review and meta-analysis of randomized controlled trials2025 · 3 citations
  2. 2Invasive Fungal Infections Following Bruton Tyrosine Kinase Inhibitor Treatment: A Systematic Review and Meta-analysis2026
  3. 3Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi.2024
  4. 4Risk of new-onset hypertension in patients (pts) with newly diagnosed chronic lymphocytic leukemia (CLL) treated with Bruton tyrosine kinase inhibitors (BTKi): A real-world data study using the Symphony Health Solution database.2024
  5. 5The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk2026